Ascensia launches six-month Eversense CGM system in the US

Ascensia Diabetes Care announced Monday that it has launched the next-generation Eversense E3 continuous glucose monitoring (CGM) system in the US, alongside a new payment assistance programme to help bolster access. The FDA earlier this year approved Eversense E3, which was developed by Senseonics, for use up to six months.

"As the longest-lasting CGM system available…Eversense E3's offering is truly differentiated and we believe it is important to make the system as affordable as possible," remarked Ascensia president Robert Schumm.

The third-generation sensor is indicated for continually measuring glucose levels for up to 180 days in diabetes patients aged 18 and older, with Senseonics previously noting that the product's performance matches that of the older 90-day model, which was also fully-implantable. The new system includes a fluorescence-based sensor and removable smart transmitter that provides on-body vibe alerts and sends data to a mobile app. According to Ascensia, E3 requires two sensor insertion and removal procedures per year, with fingerstick glucose measurements required for calibration primarily once a day after 21 days of use.

Meanwhile, Ascensia also introduced the so-called PASS programme to increase patient access to the Eversense E3 system. The programme will allow Eversense users to pay $99 out-of-pocket for their first E3 sensor and smart transmitter, and no more than $100 per month for each sensor thereafter, or $600 for the duration of each sensor wear. 

Don't want to miss our top stories? Sign up for our free daily newsletter here.